Transplantation of ex vivo gene-corrected autologous cells represents an attractive therapeutic approach for brain diseases. Among the cells of the central nervous system, brain macrophages are promising candidates due to their role in tissue homeostasis and their implication in several neurological diseases. Up to now, gene transfer into macrophages has proven difficult by most currently available gene delivery methods. We describe herein, an efficient transduction of rat bone marrow-derived and brain macrophages with an HIV-1-derived vector containing a central DNA flap and encoding the GFP reporter gene (TRIP-⌬U3-GFP). In primary cultures of macrophages our results show that more than 90% of the cells were transduced by the TRIP vector and that GFP
Introduction
The transfer of therapeutic genes into CNS-homing cells is a promising approach for brain therapy. Numerous cell types such as neural progenitors, astrocytes, fibroblasts and immortalized cells have been genetically modified for their further transplantation into the rat brain. [1] [2] [3] [4] [5] [6] For example, in a rat model of Parkinson's disease, the intrastriatal graft of dopaminergic embryonic neurons expressing the human Cu/Zn superoxide dismutase gene, was found to improve cell survival and to correct motor symptoms partially. 7, 8 In the same model, the graft of astrocytes expressing tyrosine hydroxylase significantly improved motor deficits. 1 Other CNS diseases like peroxisomal or abnormal lysosomal storage are known to involve macrophage defects. 9, 10 In the murine Gaucher disease, it has been reported that glucocerebrosidase-transduced mononuclear phagocytes injected intravenously migrated into the brain. 9, 11 However, only partial improvement of the neurological deficits were observed, due to the limited penetration of systemically delivered transduced macro- phages into the brain. 9, [11] [12] [13] [14] In order to target the therapeutic action of genetically modified macrophages on brain tissues, we have used an alternative approach by injecting transduced autologous macrophages directly into the brain.
Transduction of cells must combine efficient gene delivery and long-term gene expression without inflammatory process. Herpes simplex and adenoviral vectors provide efficient cell transduction, but their use may be restricted in vivo due to their inherent immunogenicity. 15, 16 Recently, Costantini et al 17, 18 have shown that a herpes simplex virus/adeno-associated virus amplicon vector injected directly into the brain allowed stable expression of the transgene without inflammatory process. Other studies have used retroviral vectors derived from Moloney murine leukemia virus 19, 20 or lentiviruses. 21, 22 The latter vectors are valuable tools due to their ability to transduce non-dividing cells, such as neurons and macrophages. [21] [22] [23] [24] We have reported that the insertion of the DNA flap sequence into a previously described HIV-1 derived vector 22 strongly stimulates in vitro transduction. 25, 26 The high efficiency of gene transfer is provided by the triplestranded DNA flap sequence which increases the nuclear import rate of the TRIP vector DNA into the nucleus of target cells.
In the present study, we show that a self-inactivating TRIP vector, expressing the GFP reporter gene, transduced macrophages derived from bone marrow (BMDM) or embryonic brain (bM) in an efficient and stable manner in vitro. In vivo, transplants of transduced macrophages into the striatum of adult rats showed long-term expression of GFP up to 3 months without any significant sign of astrogliosis. Thus, such transduced macrophages appear as particularly attractive vehicles for long-term gene expression into the brain.
Results

Highly efficient gene transfer into primary cultures of brain (bM) or bone marrow-derived macrophages (BMDM)
Non-dividing terminally differentiated bM and BMDM were transduced with a TRIP vector deleted in the U3 region of the LTR and expressing the GFP reporter gene under the control of the CMV internal promoter. 27 TRIP vector particles were pseudotyped using the VSV-G envelope protein. 28 Three, 10 and 15 days after transduction, FACS analysis was performed to assess gene transfer by detection of GFP fluorescence. We observed that more than 90% of both BMDM (Figure 1a ) or bM ( Figure  1b ) were transduced using a concentration of TRIP vector particles corresponding to as little as 30 ng/ml of p24. Pseudotransduction of GFP was assayed by treating cells, before the transduction, with 1 m nevirapine (Boehringer Ingelheim, Ridgefield, CT, USA), an HIV-1 reverse transcriptase inhibitor. The weak signal observed 3 days after transduction in the presence of nevirapine became undetectable 15 days after transduction, whereas a strong GFP signal was still detected in the absence of nevirapine up to 1 month after transduction (data not shown). The sustained GFP expression in vitro and the cell viability for up to 1 month after transduction was indicative of the absence of lentiviral vector toxicity in the primary BMDM or bM cultures.
Characterization of the population of transduced cells
The purity of primary cultures of BMDM and bM cells was assessed using macrophage monoclonal antibodies. ED1 recognizes a single chain glycoprotein expressed predominantly on the lysosomal membrane of macrophages and Mac-1 labels, a cell surface protein present on resident or activated macrophages. As shown in Figure 2 , whole cells were stained with ED1 and Mac-1 antibodies, indicating that they belonged to the mononuclear phagocyte lineage. Almost all cells expressed GFP when observed by confocal microscopy, thus confirming the highly efficient gene transduction by the TRIP vector. The BMDM cells exhibited a rounded cell morphology with a large cytoplasm (Figure 2a 
Long-term survival of transplanted cells into the brain
The highly efficient transduction of primary macrophages allowed us to investigate the effects of intracerebral engraftment of macrophages into the rat striatum. In order to minimize the volumetric constraints of injections into the brain, 2 l of a concentrated cell suspension Gene Therapy (2.5 × 10 7 cells/ml) were injected into the brain. The GFPpositive BMDM or bM cells were injected into the right striatum, whereas control untransduced cells ( Figure 3a and c (BMDM); e and g (bM)) or PBS were injected into the contralateral striatum. Animals were killed at 5, 15, 30 and 90 days after transplantation and brain sections were analyzed by confocal microscopy as described in Materials and methods.
For each transplanted cell type, the GFP fluorescence was detected around the injection site at day 5 ( Figure  3b and f) , and at day 15 and 30 (data not shown). At day 90, GFP-positive cells surrounding the injection site were still present, thus indicating sustained GFP expression and long-term cell survival, together with no or limited cell migration (Figure 3d and h) . It is noteworthy that at day 90 as compared with day 5 most of the transplanted bM cells exhibited an intense ramified phenotype as shown on Figure 3h . The BMDM adopted the same phenotype, but the ramifications were less extended than for the bM (Figure 3d ).
Immunohistochemical analysis of transplanted cells
The phenotype of transplanted BMDM or bM cells was characterized using ED1 and Mac-1 antibodies. At day 5, we observed that bM expressing GFP were both ED1 and Mac-1 positive (Figure 4a and b) . Additional ED1 and Mac-1-positive cells were also observed which might correspond to resident macrophages or monocytes that have infiltrated the tissue as a consequence of a local inflammatory process.
At day 90, all the GFP-expressing cells were strongly Mac-1-positive (Figure 3d ), but the ED1 staining decreased dramatically (Figure 3c ). This observation suggests that the resting ramified phenotype adopted by the bM cells at day 90 is the result of the integration of the cells in the brain microenvironment. Moreover, no longer local inflammation process was detected indicating the presence of local and transient monocytes/macrophages infiltration due to the inflammation caused by the injection needle.
For BMDM cells, similar results were obtained both at day 5 and at day 90 after transplantation (data not shown).
Assessment of the astrocytic gliosis
In numerous brain transplantation studies in animals, local astrocytic gliosis is a well-known phenomenon which needs to be monitored for gene therapy applications. We therefore examined each transplanted brain section for astrocytes reactivity as an assessment of local astrocytic gliosis using the GFAP astrocytic marker. Enhanced GFAP staining was observed around the injection site 5 days after PBS injection (data not shown), as well as after the graft of untransduced (Figure 5a ) or transduced cells (Figure 5b ). Extensive GFAP staining was no longer detectable at days 15 and 30 (data not shown), nor at day 90 (Figure 5c and d) . Therefore, the local and transient astrocytic gliosis can be interpreted as the consequence of the mechanical trauma caused by the injection needle.
Discussion
In the present study, we showed that an HIV-1-derived TRIP vector, including the triple-stranded DNA flap, allowed highly efficient ex vivo transduction of primary macrophages derived from bone marrow, as well as from fetal brain, without cytopathic effect. In vivo, following injection of the transduced macrophages into the rat striatum, stable transgene expression was observed from 5 to 90 days. At day 5, GFAP staining revealed local astrogliosis around the injection site, which was no longer detectable at days 15, 30 or 90. At day 90, transplanted cells exhibited an intense ramified phenotype in accordance with the absence of inflammatory process or astrogliosis. Moreover, grafted macrophages remained localized around the injection site. These results are indicative of the long-term survival and successful adaptation of the transduced cells to the brain tissue environment.
Among currently available methods of gene delivery, lentiviruses represent a valuable tool for genetic engineering of cells. 29, 30 We have recently established that the insertion of the DNA flap sequence, a determinant of lentiviral genome nuclear import, into a previously described HIV-1 vector 22 increases transduction efficiency. 25 As demonstrated by this study, the high transduction rate of macrophages make them attractive vehicles for autologous transplantation into the brain. Macrophages play a crucial role in many brain pathologies including neurodegenerative and neurological dis- eases. 31, 32 Repopulation of the CNS mononuclear system is a critical issue in the treatment of lysosomal storage diseases by bone marrow transplantation. 9, 11, 31, 33 Recent efforts in the treatment of these diseases have focused on the concept of gene therapy, in which the patient's genetically deficient bone marrow cells are transduced in vitro and reinjected by the systemic route to the subject. 33 Despite substantial progress towards this goal, ex vivo gene therapy of the brain using such an approach has proven to be limited by the poor penetration of macrophages through the blood-brain barrier and by their slow turnover into the brain. Direct injection into the brain of stably transduced macrophages would represent an alternative way for intracerebral functional complementation. Such an approach is in progress, acccording to the recent reports of successful brain therapy using direct injection of lentiviral vector delivering GDNF or intracerebral neuron complementation in neurodegenerative diseases. 34, 35 As opposed to what has been described in the case of astrocyte transplantation, 36 we observed that macrophages did not migrate at a great distance from the injection site. This feature is important for targeting specific brain areas in pathologies where the genetic delivery system must be localized such as in Parkinson's, Tay-Sachs or Sandhoff's diseases. 31 As shown here, modified-macrophage transplants could provide local delivery of the gene of interest in the target CNS structure.
Figure 2 Immunocytochemical characterization of primary bone marrow derived (BMDM) or brain (bM) macrophages transduced with the TRIP-⌬U3-GFP vector. Primary BMDM (a and b) or bM (c and d) macrophages were subjected to immunocytochemistry with ED1 (a, c) or Mac-1 (b, d) antibodies 3 days after transduction. Fluorescence was analyzed on a confocal microscope using 488 or 543 wave lengths for GFP and ED1 or
Gene therapy methods using macrophage transplants offer several advantages. Macrophages are an easy and abundant cell source and can be efficiently transduced with HIV-1 derived TRIP vectors. (10 m) at 5 (a, b, e, f)  or 90 days (c, d, g, h) after intracerebral engraftment. Magnification ×40.
Gene Therapy
Figure 3 GFP expression by transplanted bone marrow-derived (BMDM) and brain (bM) macrophages into the rat striatum. Rats were grafted with not transduced BMDM (a, c) or bM (e, g) or with TRIP-⌬U3-GFP transduced BMDM (b, d) or bM (f, h). Brain sections were analyzed for GFP fluorescence by 3-D view on a confocal microscope
Materials and methods
Primary cultures of brain-derived macrophages (bM) and bone marrow-derived macrophages (BMDM)
Primary mixed brain (bM) cell cultures were generated from cerebral cortices and striata of 17-day-old (E17) Wistar rat embryos (IFFA CREDO, L'Arbresle, France) as previously described. 37 Briefly, the cell suspension was cul- tured in DMEM supplemented with 2 mm l-glutamine, 20 mm NaHCO 3 , 5 U/ml penicillin, 50 g/ml streptomycin and 10% heat-inactivated fetal calf serum. All cell culture reagents were from Life Technologies (Cergy Pontoise, France). Floating bM were isolated from a 2-week culture, by shaking for 30 min at room temperature, and replated on to uncoated six-well dishes (10 6 cells/ml). Cells were left to adhere for 3 days before being transduced. Bone marrow cells were collected from femurs and tibias of old male Long-Evans rats (Janvier, Le Genest-StIsle, France) as previously described. 37, 38 Briefly, cells were flushed out with a 25-gauge needle into ice-cold phosphate-buffered saline (PBS) without Mg ++ , Ca
++
. The marrow plugs were centrifuged (1500 g, 10 min, 4°C). After dissociation of the cells and elimination of red cells, bone marrow cells were seeded into six-well dishes (4 × 10 6 cells/ml; Costar, Cambridge, MA, USA) in RPMI 1640 (Seromed, Berlin, Germany) supplemented as above and containing 5% of a conditioned medium from L929, as a source of CSF-1. 39 At day 3, adherent and differentiated BMDM were then used for transduction.
For immunofluorescence studies, glass coverslips were placed into the wells of culture plates. For in vivo transplantation, the cells were detached with trypsin-EDTA 1X, washed and resuspended in serum and CSF-1-free medium at 2.5 × 10 7 cells/ml.
Lentiviral vector production
Lentiviral vector stocks were produced as previously described, 22 with minor modifications. 25 P8.2 was used as packaging plasmid. 22 Vector particles were pseudotyped with the VSV envelope protein using pCMV-G expression plasmid. 28 Vector RNA genomes were provided by co-transfection of pTRIP-⌬U3-CMV-GFP, a self inactivating version of pTRIP. 27 
Cell transduction and quantitation of gene transfer efficiency
In vitro transduction experiments were conducted in sixwell plates. BMDM and bM cells were transduced at a vector particle concentration corresponding to 30 ng of p24 antigen per milliliter.
Transduction efficiency was evaluated using flow cytometry. GFP fluorescence was measured in BMDM and bM on a FACS and analyzed with the CellQuest software (Becton-Dickinson, Le Pont de Claix, France). Pseudotransduction of GFP was quantified after transduction of cells treated by 1 mm nevirapine, a non-nucleosidic HIV-1 reverse transcriptase inhibitor. After suitable gating, 10 000 events were collected for each experiment. R1 represents the mononuclear phagocyte population selected except lymphocytes and dead cells. In FL1-height GFP autofluorescence activity was gated while FL2-height counted Mac-1/TRITC labeled macrophage/microglial cells. In plots the black bars were defined from the double-negative population for FL1 and FL2-height. Statistics plots determined the rate of gated cells and fluorescence intensity in the four different quadrants (LL, low left; LR, low right; UL, up left; and UR, up right).
Intracerebral macrophage transplantation
Autologous engraftments were performed using bM or BMDM transplanted into the brain of Wistar (n = 20) or Long-Evans (n = 20) rats. Male adult rats (250-300 g) were anesthetized with sodium pentobarbital (50 mg/kg; Sanofi, France), and positioned in a stereotactic frame as previously described. 40, 41 Holes were drilled in the appropriate locations and a 10-l Hamilton syringe was used to inject 2 l of cell suspension into the striatum (AP +1.8; L ±2.6; DV Ϫ 4.5) at a slow time course (0.2 l/min). At the cessation of the injection, the needle was left in place for 15 min before withdrawal. GFP-transduced macrophages were injected into the right striatum and control untransduced cells or PBS were injected into the left striatum. No behavioral abnormalities in daily activities or changes in body weight could be observed following transplantation over the study period.
For each type of engraftment, five rats were perfused intracardially with 4% PFA at day 5, 15, 30 and 90, respectively. Brains were removed, dipped in 20% sucrose solution, frozen in Tissue-tek OCT (Miles, Elkhart, IN, USA) and stored at Ϫ80°C.
Immunocytochemical procedures
In vitro, BMDM and bM were washed, fixed in 4% PFA for 10 min at room temperature and rinsed with PBS. The cells were then treated with a blocking solution containing 10% goat serum and 0.2% Triton X-100 in PBS. For characterization of macrophages, the cells were incubated with mouse IgG anti-rat ED1 or Mac-1 (Serotec, Oxford, UK, diluted 1:100 in blocking solution). 42, 43 Next, the secondary antibody Cy3-conjugated affiniPure goat antimouse IgG (Beckman Coulter, Roissy, France) diluted 1:500 in blocking solution was added to the cells. The glass coverslips were mounted in Fluosave Reagent (Calbiochem, Meudon, France) and stored at Ϫ20°C.
For in situ immunohistochemistry, coronal OCT-coated brain slices (cryostat, 25 m) were rehydrated in PBS and treated for immunohistochemistry as described above. The antibody specific for the astrocytic marker GFAP (diluted 1:400 in blocking solution, Chemicon, France) was used to detect inflammatory process. 44 
Confocal microscopy
For immunohistochemical analysis, a confocal scanning laser microscope (Zeiss, Le Pecq, France) was used for fluorescence detection. 2-D optical sections were acquired with the LSM 510 software (Zeiss). For double-label immunofluorescence, the 488 and 543 lines were used in alternating acquisition mode.
